The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The impact of prophylactic immunoglobulin on infection burden with bispecific antibodies in myeloma
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, shares real-world insights on infection risk in patients with multiple myeloma treated with bispecific antibodies, particularly BCMA-targeting agents. He highlights the role of immunoglobulin replacement in reducing infections. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
